Optimization of pressurized liquid extraction using a multivariate chemometric approach and comparison of solid phase extraction cleanup steps for the determination of polycyclic aromatic hydrocarbons in mosses

A factorial design was used to optimize the extraction of polycyclic aromatic hydrocarbons (PAHs) from mosses, plants used as biomonitors of air pollution. The analytical procedure consists of pressurized liquid extraction (PLE) followed by solid-phase extraction (SPE) cleanup, in association with analysis by high performance liquid chromatography coupled with fluorescence detection (HPLC-FLD). For method development, homogeneous samples were prepared with large quantities of the mosses Isothecium myosuroides Brid. and Hypnum cupressiforme Hedw., collected from a Spanish Nature Reserve. A factorial design was used to identify the optimal PLE operational conditions: 2 static cycles of 5 min at 80°C. The analytical procedure performed with PLE showed similar recoveries (∼70%) and total PAH concentrations (∼200 ng g-1) as found using Soxtec extraction, with the advantage of reducing solvent consumption by 3 (30 mL against 100 mL per sample), and taking a fifth of the time (24 samples extracted automatically in 8 h against 2 samples in 3.5 h). The performance of SPE normal phases (NH2, Florisil®, silica and activated aluminium) generally used for organic matrix cleanup was also compared. Florisil® appeared to be the most selective phase and ensured the highest PAH recoveries. The optimal analytical procedure was validated with a reference material and applied to moss samples from a remote Spanish site in order to determine spatial and inter-species variability

Sorting Integers on the AP1000

Sorting is one of the classic problems of computer science. Whilst well understood on sequential machines, the diversity of architectures amongst parallel systems means that algorithms do not perform uniformly on all platforms. This document describes the implementation of a radix based algorithm for sorting positive integers on a Fujitsu AP1000 Supercomputer, which was constructed as an entry in the Joint Symposium on Parallel Processing (JSPP) 1994 Parallel Software Contest (PSC94). Brief consideration is also given to a full radix sort conducted in parallel across the machine.Comment: 1994 Project Report, 23 page

Microarray analysis of spring barley cultivars displaying differing sensitivity to physiological leaf spot (PLS)

peer-reviewedPhysiological leaf spot (PLS) is a disorder of spring barley (Hordeum vulgare L.), which has become more pronounced in recent years. The initial symptoms are small chlorotic/brown spots on the upper four leaves, which may develop into necrotic lesions with an irregular shape. As PLS occurs on leaves that are directly exposed to sunlight, it is thought that high light stress could be a trigger for the condition. This study concentrates on two cultivars, Cooper and Crusader, which display differential sensitivity to PLS. Biochemical measurements and enzyme assays revealed substantial difference in levels of ascorbate, type III peroxidases, and superoxide dismutase between the chosen cultivars during the 2003 growing season. A global gene expression study, using these field samples, was performed by microarray analysis. This supported the biochemical findings and highlighted additional sets of genes differentially expressed between the cultivars. Transcripts of particular interest, which appeared, included calcium signalling genes, cold-responsive genes and those involved in the assembly of Photosystem I. We conclude that susceptibility to PLS is related to levels of expression of genes with a role in countering the effects of oxidative stress.Teagasc Walsh Fellowship Programm

Paying for Permanence: Public Preferences for Contaminated Site Cleanup

We use conjoint choice questions to investigate people’s preferences for income and reductions in mortality risks delivered by contaminated site remediation policies. Our survey is self-administered using the computer by residents of four cities in Italy with severely contaminated sites. We estimate the Value of a Statistical Life to be about €5.6 million for an immediate risk reduction. If the risk reduction takes place 20 years from now, however, the implied VSL is about €1.26 million. The discount rate implicit in the responses to the conjoint choice questions is about 7%. People are willing to pay for permanent risk reductions, but not just any amount. Risk reductions in the nearer future are valued more highly than risk reductions in the more distant future. We also find that the VSL is “individuated,” in the sense that it depends on observable individual characteristics of the respondents, familiarity with contaminated sites, concern about the health effects of exposure to toxicants, having a family member with cancer, perceived usefulness of possible government actions, and the respondent’s beliefs about the goals of government remediation programs. Additional questions suggest that respondents discount lives, and do so at a discount rate in the ballpark of that implicit in their risk v. money tradeoffs.Value of a Statistical Life, Latent Risk Reductions, Individual Discount Rates, Conjoint Choice Questions, Contaminated Sites, Remediation

Development of a rapid LC-MS/MS Method for the determination of emerging fusarium mycotoxins enniatins and beauvericin in human biological fluids

A novel method for the simultaneous determination of enniatins A, A1, B and B1 and beauvericin, both in human urine and plasma samples, was developed and validated. The method consisted of a simple and easy pretreatment, specific for each matrix, followed by solid phase extraction (SPE) and detection by high performance liquid chromatography-tandem mass spectrometry with an electrospray ion source. The optimized SPE method was performed on graphitized carbon black cartridges after suitable dilution of the extracts, which allowed high mycotoxin absolute recoveries (76%-103%) and the removal of the major interferences from the matrix. The method was extensively evaluated for plasma and urine samples separately, providing satisfactory results in terms of linearity (R² of 0.991-0.999), process efficiency (>81%), trueness (recoveries between 85% and 120%), intra-day precision (relative standard deviation, RSD < 18%), inter-day precision (RSD < 21%) and method quantification limits (ranging between 20 ng·L(-)¹ and 40 ng·L(-)¹ in plasma and between 5 ng·L(-)¹ and 20 ng·L(-)¹ in urine). Finally, the highly sensitive validated method was applied to some urine and plasma samples from different donors

Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy - the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial

Compelling data have linked disease progression in patients with idiopathic pulmonary fibrosis (IPF) with lung dysbiosis and the resulting dysregulated local and systemic immune response. Moreover, prior therapeutic trials have suggested improved outcomes in these patients treated with either sulfamethoxazole/ trimethoprim or doxycycline. These trials have been limited by methodological concerns. This trial addresses the primary hypothesis that long-term treatment with antimicrobial therapy increases the time-to-event endpoint of respiratory hospitalization or all-cause mortality compared to usual care treatment in patients with IPF. We invoke numerous innovative features to achieve this goal, including: 1) utilizing a pragmatic randomized trial design; 2) collecting targeted biological samples to allow future exploration of 'personalized' therapy; and 3) developing a strong partnership between the NHLBI, a broad range of investigators, industry, and philanthropic organizations. The trial will randomize approximately 500 individuals in a 1:1 ratio to either antimicrobial therapy or usual care. The site principal investigator will declare their preferred initial antimicrobial treatment strategy (trimethoprim 160 mg/ sulfamethoxazole 800 mg twice a day plus folic acid 5 mg daily or doxycycline 100 mg once daily if body weight is < 50 kg or 100 mg twice daily if ≥50 kg) for the participant prior to randomization. Participants randomized to antimicrobial therapy will receive a voucher to help cover the additional prescription drug costs. Additionally, those participants will have 4-5 scheduled blood draws over the initial 24 months of therapy for safety monitoring. Blood sampling for DNA sequencing and genome wide transcriptomics will be collected before therapy. Blood sampling for transcriptomics and oral and fecal swabs for determination of the microbiome communities will be collected before and after study completion. As a pragmatic study, participants in both treatment arms will have limited in-person visits with the enrolling clinical center. Visits are limited to assessments of lung function and other clinical parameters at time points prior to randomization and at months 12, 24, and 36. All participants will be followed until the study completion for the assessment of clinical endpoints related to hospitalization and mortality events. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT02759120